SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Jubilant Pharmova - Quaterly Results

02 Aug 2022 Evaluate
A fair growth of 14.52% in the revenue at Rs. 2045.70 millions was reported in the June 2022 quarter as compared to Rs. 1786.40 millions during year-ago period.The Net Loss for the quarter ended June 2022 is Rs. -51.80 millions as compared to Net Loss of Rs. -7.60 millions of corresponding quarter ended June 2021The Operating Profit of the company witnessed a decrease to 58.70 millions from 108.40 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 2045.70 1786.40 14.52 2045.70 1786.40 14.52 877.50 27095.00 -96.76
Other Income 102.40 42.80 139.25 102.40 42.80 139.25 1258.70 478.80 162.89
PBIDT 58.70 108.40 -45.85 58.70 108.40 -45.85 1190.90 4749.40 -74.93
Interest 31.50 26.70 17.98 31.50 26.70 17.98 305.90 1018.00 -69.95
PBDT 27.20 81.70 -66.71 27.20 81.70 -66.71 885.00 3731.40 -76.28
Depreciation 92.10 91.60 0.55 92.10 91.60 0.55 62.50 999.70 -93.75
PBT -64.90 -9.90 555.56 -64.90 -9.90 555.56 822.50 2731.70 -69.89
TAX -13.10 -2.30 469.57 -13.10 -2.30 469.57 37.50 586.90 -93.61
Deferred Tax -13.10 -3.20 309.38 -13.10 -3.20 309.38 -99.10 132.50 -174.79
PAT -51.80 -7.60 581.58 -51.80 -7.60 581.58 785.00 2144.80 -63.40
Equity 159.30 159.30 0.00 159.30 159.30 0.00 159.30 159.30 0.00
PBIDTM(%) 2.87 6.07 -52.71 2.87 6.07 -52.71 135.72 17.53 674.25

Jubilant Pharmova Share Price

907.30 2.90 (0.32%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×